Cargando…

Enzymatically amplified linear dbDNA(TM) as a rapid and scalable solution to industrial lentiviral vector manufacturing

Traditional bacterial fermentation techniques used to manufacture plasmid are time-consuming, expensive, and inherently unstable. The production of sufficient GMP grade material thus imposes a major bottleneck on industrial-scale manufacturing of lentiviral vectors (LVV). Touchlight’s linear doggybo...

Descripción completa

Detalles Bibliográficos
Autores principales: Barreira, Maria, Kerridge, Claire, Jorda, Sara, Olofsson, Didrik, Neumann, Alexander, Horton, Helen, Smith-Moore, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935383/
https://www.ncbi.nlm.nih.gov/pubmed/35606492
http://dx.doi.org/10.1038/s41434-022-00343-4
_version_ 1784890017408090112
author Barreira, Maria
Kerridge, Claire
Jorda, Sara
Olofsson, Didrik
Neumann, Alexander
Horton, Helen
Smith-Moore, Sarah
author_facet Barreira, Maria
Kerridge, Claire
Jorda, Sara
Olofsson, Didrik
Neumann, Alexander
Horton, Helen
Smith-Moore, Sarah
author_sort Barreira, Maria
collection PubMed
description Traditional bacterial fermentation techniques used to manufacture plasmid are time-consuming, expensive, and inherently unstable. The production of sufficient GMP grade material thus imposes a major bottleneck on industrial-scale manufacturing of lentiviral vectors (LVV). Touchlight’s linear doggybone DNA (dbDNA(TM)) is an enzymatically amplified DNA vector produced with exceptional speed through an in vitro dual enzyme process, enabling industrial-scale manufacturing of GMP material in a fraction of the time required for plasmid. We have previously shown that dbDNA(TM) can be used to produce functional LVV; however, obtaining high LVV titres remained a challenge. Here, we aimed to demonstrate that dbDNA(TM) could be optimised for the manufacture of high titre LVV. We found that dbDNA(TM) displayed a unique transfection and expression profile in the context of LVV production, which necessitated the optimisation of DNA input and construct ratios. Furthermore, we demonstrate that efficient 3’ end processing of viral genomic RNA (vgRNA) derived from linear dbDNA(TM) transfer vectors required the addition of a strong 3’ termination signal and downstream spacer sequence to enable efficient vgRNA packaging. Using these improved vector architectures along with optimised transfection conditions, we were able to produce a CAR19h28z LVV with equivalent infectious titres as achieved using plasmid, demonstrating that dbDNA(TM) technology can provide a highly effective solution to the plasmid bottleneck.
format Online
Article
Text
id pubmed-9935383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99353832023-02-18 Enzymatically amplified linear dbDNA(TM) as a rapid and scalable solution to industrial lentiviral vector manufacturing Barreira, Maria Kerridge, Claire Jorda, Sara Olofsson, Didrik Neumann, Alexander Horton, Helen Smith-Moore, Sarah Gene Ther Article Traditional bacterial fermentation techniques used to manufacture plasmid are time-consuming, expensive, and inherently unstable. The production of sufficient GMP grade material thus imposes a major bottleneck on industrial-scale manufacturing of lentiviral vectors (LVV). Touchlight’s linear doggybone DNA (dbDNA(TM)) is an enzymatically amplified DNA vector produced with exceptional speed through an in vitro dual enzyme process, enabling industrial-scale manufacturing of GMP material in a fraction of the time required for plasmid. We have previously shown that dbDNA(TM) can be used to produce functional LVV; however, obtaining high LVV titres remained a challenge. Here, we aimed to demonstrate that dbDNA(TM) could be optimised for the manufacture of high titre LVV. We found that dbDNA(TM) displayed a unique transfection and expression profile in the context of LVV production, which necessitated the optimisation of DNA input and construct ratios. Furthermore, we demonstrate that efficient 3’ end processing of viral genomic RNA (vgRNA) derived from linear dbDNA(TM) transfer vectors required the addition of a strong 3’ termination signal and downstream spacer sequence to enable efficient vgRNA packaging. Using these improved vector architectures along with optimised transfection conditions, we were able to produce a CAR19h28z LVV with equivalent infectious titres as achieved using plasmid, demonstrating that dbDNA(TM) technology can provide a highly effective solution to the plasmid bottleneck. Nature Publishing Group UK 2022-05-24 2023 /pmc/articles/PMC9935383/ /pubmed/35606492 http://dx.doi.org/10.1038/s41434-022-00343-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Barreira, Maria
Kerridge, Claire
Jorda, Sara
Olofsson, Didrik
Neumann, Alexander
Horton, Helen
Smith-Moore, Sarah
Enzymatically amplified linear dbDNA(TM) as a rapid and scalable solution to industrial lentiviral vector manufacturing
title Enzymatically amplified linear dbDNA(TM) as a rapid and scalable solution to industrial lentiviral vector manufacturing
title_full Enzymatically amplified linear dbDNA(TM) as a rapid and scalable solution to industrial lentiviral vector manufacturing
title_fullStr Enzymatically amplified linear dbDNA(TM) as a rapid and scalable solution to industrial lentiviral vector manufacturing
title_full_unstemmed Enzymatically amplified linear dbDNA(TM) as a rapid and scalable solution to industrial lentiviral vector manufacturing
title_short Enzymatically amplified linear dbDNA(TM) as a rapid and scalable solution to industrial lentiviral vector manufacturing
title_sort enzymatically amplified linear dbdna(tm) as a rapid and scalable solution to industrial lentiviral vector manufacturing
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935383/
https://www.ncbi.nlm.nih.gov/pubmed/35606492
http://dx.doi.org/10.1038/s41434-022-00343-4
work_keys_str_mv AT barreiramaria enzymaticallyamplifiedlineardbdnatmasarapidandscalablesolutiontoindustriallentiviralvectormanufacturing
AT kerridgeclaire enzymaticallyamplifiedlineardbdnatmasarapidandscalablesolutiontoindustriallentiviralvectormanufacturing
AT jordasara enzymaticallyamplifiedlineardbdnatmasarapidandscalablesolutiontoindustriallentiviralvectormanufacturing
AT olofssondidrik enzymaticallyamplifiedlineardbdnatmasarapidandscalablesolutiontoindustriallentiviralvectormanufacturing
AT neumannalexander enzymaticallyamplifiedlineardbdnatmasarapidandscalablesolutiontoindustriallentiviralvectormanufacturing
AT hortonhelen enzymaticallyamplifiedlineardbdnatmasarapidandscalablesolutiontoindustriallentiviralvectormanufacturing
AT smithmooresarah enzymaticallyamplifiedlineardbdnatmasarapidandscalablesolutiontoindustriallentiviralvectormanufacturing